Predicting the benefits of type-2 targeted anti-inflammatory treatment with the prototype Oxford Asthma Attack Risk Scale (ORACLE)

The prototype ORACLE scale based on two simple measures of type 2 airway inflammation (blood eosinophils and F(ENO)) quantifies the excess risk conferred by raised biomarkers that is removed by type-2 anti-inflammatory treatment in trial populations https://bit.ly/3F1gnUl

Detalles Bibliográficos
Autores principales: Couillard, Simon, Do, William Il Hoon, Beasley, Richard, Hinks, Timothy S.C., Pavord, Ian D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2021
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8819242/
https://www.ncbi.nlm.nih.gov/pubmed/35141315
http://dx.doi.org/10.1183/23120541.00570-2021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8819242/
https://www.ncbi.nlm.nih.gov/pubmed/35141315
http://dx.doi.org/10.1183/23120541.00570-2021

Ejemplares similares